Neuphoria Therapeutics Inc. (NEUP) stock
NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
$2.55−0.03 (-1.16%)
Close on Nov 13, 2026Market cap $76.66KP/E –Yield –
Neuphoria Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Neuphoria Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$15.79M. For fiscal 2026 it was -$15.79M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$15.79M | – |
| FY2025 | Jun 30, 2025 | -$466.20K | – |
| FY2024 | Jun 30, 2024 | -$17.23M | – |
| FY2023 | Jun 30, 2023 | -$21.32M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$5.36M | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$1.05M | -108.6% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$3.90M | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$5.49M | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$5.67M | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $12.14M | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$3.54M | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$3.40M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$5.31M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$2.23M | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$4.39M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$5.30M | – |
See a number that looks wrong?